Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose low-molecular-weight heparin Certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 4, 2002, Pages 289-296

  Hoffmann, U ^a   Harenberg, Job ^a   Bauer, K ^a   Huhle, G ^a   Tolle, A R ^a   Feuring, M ^a   Christ, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Bioequivalence; Factor Xa; Low molecular weight heparin; Pharmacodynamic; Pharmacokinetic

Indexed keywords

BLOOD CLOTTING FACTOR 10A; CERTOPARIN; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EXCRETION; DRUG MEGADOSE; HEPARINIZATION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION TESTS; FACTOR XA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KINETICS; LIPOPROTEINS; MALE; PROTHROMBIN; THERAPEUTIC EQUIVALENCY; THROMBIN;

EID: 0036592642     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200206000-00003     Document Type: Article

References (31)

1. Low-molecular weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
2. Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
3. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
4. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein-thrombosis
5. Treatment of patients with proximal-vein thrombosis with intravenous unfractionated heparin in hospital compared with subcutaneous low-molecular-weight heparin out of hospital or with early discharge
6. Fixed-dose, body weight-independent subcutaneous LMW-heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis
7. Bioavailability and antagonization of the low molecular weight heparin CY 216 in man
8. Low-molecular-weight-heparin (Kabi 2165, Fragmin): Pharmocokinetics after intravenous and subcutaneous administration in human volunteers
9. Relation between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration
10. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular-weight heparin in humans given single subcutaneous doses of 20 to 80 mg
11. Pharmacokinetics and biodistribution of technitium 99m labelled standard heparin and low-molecular-weight heparin (enoxaparin) after intravenous injection in normal volunteers
12. Kinetics of radiolabelled TC-99m heparin and low-molecular-weight heparin fractions CY216 and CY222 in patients with uncomplicated myocardial infarction
13. Delayed elimination of enoxaparin in patients with renal insufficiency
14. Absolute and comparative subcutaneous bioavailability of Ardeparin sodium, a low-molecular-weight heparin
15. Comparative study on a new one-stage clotting assay for heparin and its low-molecular-weight derivates
16. Extrinsic pathway inhibitor in elective surgery: A comparison with other coagulation inhibitors
17. Modified anti-factor Xa chromogenic substrate assay for heparin and low molecular weight heparins
18. Pharmacokinetics of Clivarin a new low-molecular-weight heparin in healthy volunteers
19. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
20. Pharmacotherapeutic aspects of unfractionated and low-molecular-weight heparins
21. Comparative human pharmacology of low molecular weight heparins
22. Pharmacokinetics of low-molecular-weight heparins
23. Chemical and biological heterogeneity in low-molecular-weight heparin: Implications for clinical use and standardisation
24. Structural studies on a biologically active hexasaccharide obtained from heparin
25. Analysis of heparin binding to human leukocytes using a fluorescein-5-isothiocyanate labelled heparin fragment
26. Comparison of the non-specific binding of unfractionated heparin and low-molecular-weight heparin (Enoxaparin) to plasma proteins
27. Selective binding of heparins to human endothelial cells. Implications to pharmacokinetics
28. Heparin receptors on mouse macrophages
29. Hepatic uptake of a modified low molecular weight heparin in rats
30. Pharmacokinetic properties of size-homogeneous heparin oligosaccharides
31. Long-term persistence of biological activity following administration of Enoxaparin sodium (Clexane) is due to sequestration of antithrombin-binding low-molecular-weight fragments - Comparison with unfractionated heparin